Collaborations & Alliances

WuXi Biologics, Prima Ink Strategic Mfg. Pact

WuXi will be the exclusive clinical manufacturer for Prima’s cancer immunotherapy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and Prima Biomed Ltd. have signed an agreement to form a strategic biologics development and manufacturing partnership. Prima is developing IMP321, a recombinant soluble LAG-3 protein and other LAG-3 related products for use in oncology. WuXi Biologics will be the exclusive clinical manufacturer for IMP321 worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong, where rights are retained by Prima’s development partner, Eddingpharm. WuXi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters